Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antareit vs Riopan Pharmacodynamics in Healthy Volunteers
NCT06098742Recruiting
- Sponsor
- Valenta Pharm
- Start
- Apr 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of magaldrate in gastroesophageal reflux disease (GERD), gastric ulcer and duodenal ulcer (2 arms), sponsored by Valenta Pharm. Primary endpoints: Area under the curve potential of hydrogen, Time percentage during which the intragastric pH value will exceed 4.0 and 6 more. Started Apr 2024; status: recruiting.
02
Drugs
magaldrate
03
Conditions
gastroesophageal reflux disease (GERD)gastric ulcerduodenal ulcer
Beyond the preview
Go deeper on NCT06098742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098742.